Chiltern acquires Pacific Clinical Research Pte Limited and expands operations and therapeutic depth in Asia-Pacific

LONDON and WILMINGTON, N.C. -- Chiltern has acquired Pacific Clinical Research, a pan-Asian CRO based in Singapore. The move allows Chiltern to offer integrated services throughout the Asia-Pacific region and strengthens in particular Chiltern's oncology and anti-infective offerings.

Pacific Clinical Research founders Robert Teoh MD and Vonny Iskandar join the Chiltern management team as Managing Director, Asia-Pacific and Vice President, Asia-Pacific respectively.

The acquisition of Pacific Clinical Research comes after Chiltern's purchase of Ockham, a specialist oncology and resourcing CRO, in July and reflects Chiltern's continued commitment to offering high quality, highly responsive and tailored solutions to the global drug development industry.

Chiltern CEO Dr James Esinhart and COO Aize Smink jointly commented: "We have worked with Robert Teoh for many years and our two organisations have always collaborated well. We have been looking for some time to strengthen Chiltern's direct presence in theAsia-Pacific region, so we jumped at the opportunity to acquire Pacific and bring Robert and his team into Chiltern. We are very pleased to be able to offer customers the benefits of our merged offering with expanded access to patients and experienced research sites around Asia-Pacific."

Dr Robert Teoh added: "I am delighted to be joining the Chiltern team. Pacific Clinical Research has seen strong growth over four years and it was time for the business to integrate into a larger platform. I am excited to be leading Chiltern in the Asia-Pacific region and to be participating globally in specialized studies."

Building upon Chiltern's existing operations in India, Australia, Singapore and Taiwan, the combined company now adds direct capabilities in Hong Kong, Korea, Malaysia, Philippines and Thailand. 

About Chiltern:

Established in 1982, Chiltern is a leading global clinical CRO offering specialized services in oncology and a range of other therapeutic areas, together with global sourcing and FSP solutions. Chiltern's 2,200 people work in more than 45 countries and offer expertise, engagement and tailored, responsive solutions to meet the demands of biotech and pharmaceutical partners of all sizes.

Further information is available at:

For more information contact:

Nicholas Spittal 
Sr. Director, Global Commercial Affairs 
Chiltern International Inc. 
2528 Independence Blvd. Suite 101 
Wilmington, NC 28412 
Tel: +1 (910) 338 4760 
Email: [email protected]